Vancouver, Canada

Huifang Li

USPTO Granted Patents = 1 

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2018

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Huifang Li: Innovator in Therapeutics

Introduction

Huifang Li is a prominent inventor based in Vancouver, Canada. She has made significant contributions to the field of therapeutics, particularly in the development of compounds targeting the human androgen receptor.

Latest Patents

Huifang Li holds 1 patent for her invention titled "Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use." This patent describes a compound with a specific structure that includes substituted or unsubstituted aryl or heteroaryl groups. The compounds are designed for the treatment of various androgen-modulated conditions, including prostate, breast, ovarian, endometrial, and bladder cancers, as well as hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, and age-related macular degeneration. The patent also outlines methods for modulating androgen receptor activity and the manufacture of medicaments using these compounds.

Career Highlights

Huifang Li is affiliated with the University of British Columbia, where she continues her research and development in the field of therapeutics. Her work has garnered attention for its potential impact on treating significant health issues related to androgen modulation.

Collaborations

Some of her notable coworkers include Artem Tcherkassov and Paul Rennie, who have collaborated with her on various research projects.

Conclusion

Huifang Li's innovative work in developing androgen receptor-targeting compounds showcases her commitment to advancing therapeutic options for patients. Her contributions are paving the way for new treatments in critical areas of health.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…